Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Filament Health Corp (OP: FLHLF )

0.0334 +0.0034 (+11.33%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Filament Health Corp

< Previous 1 2 3 Next >
Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia
Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH 
Via Benzinga
EXCLUSIVE: Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits
(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is... 
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. 
Via Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights 
Via Benzinga
Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal. 
Via Benzinga
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Natural Psychedelics Extraction & Standardization Obtains Two New US Patents
Clinical-stage psychedelics drug development company Filament Health Corp. 
Via Benzinga
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics 
Via Benzinga
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September... 
Via Benzinga
Psyched: Brock Pierce Joins Psychedelic VC, Colorado's Psychedelics Legalization, Zappy Zapolin's Open Letter & More
Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable' 
Via Benzinga
EXCLUSIVE: Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'
Brock Pierce, the crypto billionaire, economist and philanthropist serving as chairman of the Bitcoin Foundation, has joined Jeremy Gardner’s psychedelics-focused venture fund Mystic Ventures as a... 
Via Benzinga
Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs
Clinical-stage natural psychedelics company Filament Health Corp. 
Via Benzinga
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment. 
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Two Psychedelics Drug Development Companies Work To Produce Novel Plant-Based Compounds For Mental Health Disorders
Filament Health Corp. (OTCQB: FLHLF) and Jaguar Health, Inc. (NASDAQ: JAGX) have signed a letter of intent for a collaboration agreement. 
Via Benzinga
Optimi Health Signs Two New Supply Agreements In Less Than a Week
Optimi (OPTHF), the Canadian, home-grown mushroom formulations producer has signed not one but two supply deals with different research companies. 
Via Benzinga
Patents In The Psychedelics Space: Good Or Bad? It's Complicated, Here's What The Experts Say
Patents are the golden eggs of the booming psychedelic space. 
Via Benzinga
Filament Health Keeps Adding Patents To Its Portfolio, Just Received Its Fourth
Just two weeks ago, Filament Health (OTCQB: FLHLF) was issued a patent by the U. S. Patent and Trademark Office to extract and standardize natural psilocybin. 
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Filament Health Talks Psilocybins, Psilocins And How Natural Psychedelics Could Conquer The Market
Filament Health (OTCQB: FLHLF) (NEO:FH) is a clinical-stage psychedelic drug development company creating safe, standardized, naturally-derived psychedelic medicines. 
Via Benzinga
Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know
Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the... 
Via Benzinga
Filament Health Acquires Patent For Extracting And Standardizing Natural Psilocybin
Filament Health Corp. (OTCQB: FLHLF) announced that the U. S. Patent and Trademark Office (USPTO) issued a patent that will allow the company to extract and standardize natural psilocybin and... 
Via Benzinga
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE. 
Via Benzinga
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants. 
Via Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov... 
Via Benzinga
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions
Image by Mathew Schwartz from Unsplash The following post was written and/or pu... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.